Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qufu Shengji Dan is a traditional Chinese medicinal (TCM) topical formulation developed as an in-hospital preparation by the Chongqing Orthopaedic Hospital of Traditional Chinese Medicine. It is primarily indicated for the treatment of chronic, non-healing wounds such as diabetic foot ulcers (DFU). The formulation follows the TCM principle of "removing putrefaction and promoting granulation" (Qufu Shengji), aimed at clearing necrotic tissue and accelerating the formation of granulation tissue and epithelialization. Clinical research suggests its mechanism involves modulating the expression of growth factors like Vascular Endothelial Growth Factor (VEGF) and Transforming Growth Factor-beta (TGF-β), while reducing inflammatory markers like TNF-α and IL-6 to improve the microenvironment of the wound bed.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on qufu shengji dan.